Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "regulation-30"

4 News Found

Fischer Medical converts warrants into equity, infuses Rs 10.53 crore
News | April 07, 2026

Fischer Medical converts warrants into equity, infuses Rs 10.53 crore

Board approves allotment of shares to promoter Shankar Varadharajan following warrant conversion under SEBI Regulation 30 disclosure

Max Healthcare allots 57,461 equity shares under ESOP 2022
Hospitals | April 05, 2026

Max Healthcare allots 57,461 equity shares under ESOP 2022

Paid-up equity capital rises to Rs 973.19 crore following allotment to eligible employees

Concord Biotech acquires Celliimune to accelerate DNA-engineered cancer therapies
Biotech | April 04, 2026

Concord Biotech acquires Celliimune to accelerate DNA-engineered cancer therapies

Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy

Zydus receives EIR for the transdermal manufacturing facility
Drug Approval | October 02, 2024

Zydus receives EIR for the transdermal manufacturing facility

This facility underwent an inspection from 15th to 19th July 2024 and has been classified as Voluntary Action Indicated

Latest Stories

Symeres and Ambagon team up to target ‘undruggable’ proteins in colorectal cancer

World Health Day: Late diagnosis, rising lifestyle diseases put young India at risk

Fischer Medical converts warrants into equity, infuses Rs 10.53 crore

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging